Document Detail


Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholesterolemia.
MedLine Citation:
PMID:  3207437     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
29 patients with primary hypercholesterolemia were treated for 8 weeks each with either bezafibrate (200 mg t.i.d.) or gemfibrozil (600 mg b.i.d.) in a randomized cross-over trial. Compared to placebo bezafibrate was significantly more effective on low density lipoprotein (LDL)-cholesterol (-28% versus -18%) and the LDL/high density lipoprotein (HDL) ratio (-34% versus -24%) by exploratory statistics. There was also a trend for a more marked reduction of bezafibrate on total cholesterol and apoliproprotein B as well as more pronounced increase in HDL-cholesterol and apolipoprotein A-I. The triglyceride reduction tended to be more extensive with gemfibrozil. Complicance to both drugs was good. No side-effects were observed. The results are considered important with respect to the potential of bezafibrate in reducing the risk of cardiovascular disease.
Authors:
P Weisweiler
Related Documents :
8536447 - The effects of nomegestrol acetate subdermal implant (uniplant) on carbohydrate metabol...
19943937 - Hypercholesterolemia and myocardial function evaluated via tissue doppler imaging.
3315677 - Report on the lipid research clinic trials.
20682487 - Changes in the lipid profile of blood serum in women taking sauna baths of various dura...
23871087 - In vivo digestion of bovine milk fat globules: effect of processing and interfacial str...
22868067 - No effects of monosodium glutamate consumption on the body weight or composition of adu...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Arzneimittel-Forschung     Volume:  38     ISSN:  0004-4172     ISO Abbreviation:  Arzneimittelforschung     Publication Date:  1988 Jul 
Date Detail:
Created Date:  1989-02-09     Completed Date:  1989-02-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372660     Medline TA:  Arzneimittelforschung     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  925-7     Citation Subset:  IM    
Affiliation:
iphar Institut für Klinische Pharmakologie GmbH, Munich, Fed. Rep. of Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antilipemic Agents / therapeutic use*
Bezafibrate / therapeutic use*
Cholesterol, LDL / blood
Female
Gemfibrozil / therapeutic use*
Humans
Hypercholesterolemia / blood,  drug therapy*
Lipoproteins / blood*
Male
Middle Aged
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Cholesterol, LDL; 0/Lipoproteins; 25812-30-0/Gemfibrozil; 41859-67-0/Bezafibrate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Disposition and metabolism of [14C]-amezinium metilsulfate in rats.
Next Document:  Double-blind study of the effect of cyclotropium bromide on the smooth musculature of the esophagus....